31 results
Thumbnail

D3.232 - The AhR agonist tapinarof suppresses human skin inflammation by inducing metabolic reprogramming and reducing production of mitochondrial pro-inflammatory DAMPs

Thumbnail

D3.231 - Gut Microbiome Dysbiosis in Antihistamine-Refractory Chronic Spontaneous Urticaria and Its Association with Disease Characteristics- A Cross-Sectional Case–Control Analysis

Thumbnail

D3.233 - Polypharmacy-Associated Lichenoid Eruption Simulating Keratosis Lichenoides Chronica

Thumbnail

D3.234 - Successful Use of Ritlecitinib in Long-Standing Alopecia Areata with Previous JAK Inhibitor Failure

Thumbnail

D3.235 - Trends in Sensitization to Preservatives and Epoxy Resins among occupationally exposed workers: A 31-Year Patch Test analysis from Tunisia

Thumbnail

D3.236 - Does Night Work Influence the Severity of Allergic Contact Dermatitis ?

Thumbnail

D3.237 - Specific Features of Allergic Contact Dermatitis in Diabetic Patients in a Dermato-Allergology Unit in Tunisia

Thumbnail

D3.238 - Allergic Contact Dermatitis to Formaldehyde: A 31-Year Experience in a Dermato-Allergology Consultation

Thumbnail

D3.239 - Foot Allergic Contact Dermatitis in Workers: Prevalence and Allergen Patterns

Thumbnail

D3.440 - Long-Term Efficacy and Safety of Donidalorsen for Hereditary Angioedema Among Patients in Europe: A Regional Analysis of the OASISplus Study

Thumbnail

D3.441 - Switching to Donidalorsen for Hereditary Angioedema: 1-Year Results From the Phase 3 OASISplus Study

Thumbnail

D3.444 - Efficacy and Safety of Donidalorsen for Patients With Hereditary Angioedema in Europe Who Switched From Prior Long-Term Prophylaxis: Results From the OASISplus Study

Thumbnail

D3.445 - Validation of a Novel Serum-Based Indirect Basophil Activation Test (iBAT) to Evaluate Efficacy of a Pivotal Phase III PQ Grass Immunotherapy Trial

Thumbnail

D3.437 - Impact of benralizumab on fatigue and health-related quality of life in patients with hypereosinophilic syndrome: findings from the NATRON phase 3 trial

Thumbnail

D3.438 - Clinical outcomes with navenibart according to baseline attack rate, body mass index, and age: results of the ALPHA-STAR trial

Thumbnail

D3.439 - Donidalorsen For The Treatment Of Hereditary Angioedema: 1-Year Results From The OASISplus Open-Label Extension Cohort

Thumbnail

D3.442 - Patient-Reported Outcomes With Long-Term Donidalorsen Treatment Among Patients In Europe With Hereditary Angioedema: 1-Year Interim Results From The OASISplus Open-Label Extension Cohort

Thumbnail

D3.443 - Patient-Reported Outcomes With Long-Term Donidalorsen Treatment Among Patients In Europe With Hereditary Angioedema: 1-Year Interim Results From The OASISplus Switch Cohort

Thumbnail

D3.446 - PROTECT Phase I/IIa Clinical Trial Demonstrated Strong Correlation Between Humoral Immune Response and Dose of VLP Peanut in Healthy Participants

Thumbnail

D3.447 - Pre-clinical Toxicology and Immunogenicity Evidence as a Precursor of the Successful Phase I/IIA Study with VLP Peanut